睿智医药：设立投资基金布局前沿项目，力争完成年度业绩目标

Core Insights - The company is collaborating with professional investment institutions to establish an investment fund through a CVC model, focusing on innovative drug projects [1] - The company aims to achieve a revenue growth rate of no less than 15% by 2025 and to turn net profit positive (excluding equity incentive expenses) [1] Group 1 - The company’s wholly-owned subsidiary is involved in the investment fund initiative [1] - The investment strategy is designed to empower industrial collaboration and expand future orders [1] - The company is advancing its operational efforts around equity incentive goals [1]